{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:12:23Z","timestamp":1790507543450,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.bulcan.2017.05.009","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T01:01:38Z","timestamp":1511744498000},"page":"S84-S98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"S","title":["Strat\u00e9gies pr\u00e9ventives et th\u00e9rapeutiques de la rechute apr\u00e8s allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)"],"prefix":"10.1016","volume":"104","author":[{"given":"Nabil","family":"Yafour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Beckerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0214-7431","authenticated-orcid":false,"given":"Claude Eric","family":"Bulabois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9tienne","family":"Daguindau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Dumesnil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula Masouridi","family":"Levrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Lise","family":"Menard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Pautas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Poir\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Ravinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2017.05.009_bib0510","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J Clin Oncol."},{"issue":"1\u00a0Suppl.","key":"10.1016\/j.bulcan.2017.05.009_bib0515","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1016\/j.bbmt.2009.10.023","article-title":"Relapse after allogeneic hematopoietic cell therapy","volume":"16","author":"van den Brink","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2017.05.009_bib0520","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.009_bib0525","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.009_bib0530","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3109\/10428194.2012.741230","article-title":"Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia","volume":"54","author":"Devillier","year":"2013","journal-title":"Leuk Lymphoma."},{"issue":"22","key":"10.1016\/j.bulcan.2017.05.009_bib0535","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2010-02-266551","article-title":"Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European group for blood and marrow transplantation","volume":"116","author":"Mohty","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib0540","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bulcan.2017.05.009_bib0545","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"334","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2017.05.009_bib0550","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017\u00a0ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.bulcan.2017.05.009_bib0555","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol."},{"issue":"7","key":"10.1016\/j.bulcan.2017.05.009_bib0560","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/leu.2016.46","article-title":"Pre- and post-transplant quantification of measurable (\u201cminimal\u201d) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia","volume":"30","author":"Zhou","year":"2016","journal-title":"Leukemia."},{"issue":"5","key":"10.1016\/j.bulcan.2017.05.009_bib0565","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.009_bib0570","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.bulcan.2017.05.009_bib0575","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bulcan.2017.05.009_bib0580","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2015.65.0515","article-title":"Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome","volume":"34","author":"Shaffer","year":"2016","journal-title":"J Clin Oncol."},{"issue":"26","key":"10.1016\/j.bulcan.2017.05.009_bib0585","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"Engl J Med."},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.009_bib0590","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib0595","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bmt.1703808","article-title":"Graft-versus-leukaemia effect in children chronic GVHD has a significant","volume":"31","author":"Gustafsson Jernberg","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.009_bib0600","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00277-013-1961-4","article-title":"Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis","volume":"93","author":"Hoffmann","year":"2014","journal-title":"Ann Hematol."},{"issue":"8","key":"10.1016\/j.bulcan.2017.05.009_bib0605","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.bmt.1704444","article-title":"Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective","volume":"33","author":"Bader","year":"2004","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"10.1016\/j.bulcan.2017.05.009_bib0610","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/bmt.2016.167","article-title":"Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"10.1016\/j.bulcan.2017.05.009_bib0615","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1182\/blood-2007-02-072470","article-title":"Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia","volume":"109","author":"Dominietto","year":"2007","journal-title":"Blood."},{"issue":"14","key":"10.1016\/j.bulcan.2017.05.009_bib0620","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2011-09-380386","article-title":"Risk stratification\u2013directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib0625","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia."},{"issue":"5","key":"10.1016\/j.bulcan.2017.05.009_bib0630","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.transproceed.2016.01.078","article-title":"Azacitidine use after allogeneic stem cell transplantation \u2013 Results from the polish adult leukemia group","volume":"48","author":"Drozd-Soko\u0142owska","year":"2016","journal-title":"Transfuspl Proceed"},{"issue":"4","key":"10.1016\/j.bulcan.2017.05.009_bib0635","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.patbio.2014.05.011","article-title":"Prophylactic, preemptive and curative use of donor lymphocyte infusion in patients undergoing allogeneic stem cell transplantation: guidelines of the SFGM-TC","volume":"62","author":"Guillaume","year":"2014","journal-title":"Pathol Biol (Paris)"},{"issue":"12","key":"10.1016\/j.bulcan.2017.05.009_bib0640","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.bbmt.2014.09.007","article-title":"Phase\u00a0I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib0645","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.14260","article-title":"Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission","volume":"175","author":"Brunner","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2017.05.009_bib0650","first-page":"3164","article-title":"Prospective study of peri-transplant use of sorafenib as remission maintenance for FLT3-ITD patients undergoing allogeneic transplantation","volume":"126","author":"Pratz","year":"2015","journal-title":"ASH"},{"issue":"5","key":"10.1016\/j.bulcan.2017.05.009_bib0655","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.clml.2014.12.005","article-title":"Sorafenib maintenance appears safe and improves clinical outcomes in FLT3-ITD acute myeloid leukemia after allogeneic hematopoietic cell transplantation","volume":"15","author":"Antar","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.bulcan.2017.05.009_bib0660","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/cncr.24198","article-title":"Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia","volume":"115","author":"Jabbour","year":"2009","journal-title":"Cancer."},{"issue":"23","key":"10.1016\/j.bulcan.2017.05.009_bib0665","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cncr.25500","article-title":"Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study","volume":"116","author":"de Lima","year":"2010","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.009_bib0670","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial","volume":"22","author":"Craddock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"10.1016\/j.bulcan.2017.05.009_bib0675","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T\u00a0cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.bulcan.2017.05.009_bib0680","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.bbmt.2010.08.001","article-title":"NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on treatment of relapse after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Porter","year":"2010","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib0685","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2003-02-0342","article-title":"Graft-versus-leukemia reactions in allogeneic chimeras","volume":"103","author":"Kolb","year":"2004","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.009_bib0690","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2002.20.2.405","article-title":"Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation","volume":"20","author":"Levine","year":"2002","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.bulcan.2017.05.009_bib0695","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol."},{"issue":"11","key":"10.1016\/j.bulcan.2017.05.009_bib0700","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.bbmt.2014.07.010","volume":"20","author":"Takami","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2017.05.009_bib0705","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/bmt.2014.300","article-title":"Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT","volume":"50","author":"Sauer","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib0710","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase\u00a0III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib0715","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase\u00a03\u00a0study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30\u00a0% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.bulcan.2017.05.009_bib0720","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica."},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.009_bib0725","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/leu.2013.7","article-title":"Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia."},{"issue":"26","key":"10.1016\/j.bulcan.2017.05.009_bib0730","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1182\/blood-2009-03-208298","article-title":"Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation","volume":"113","author":"Metzelder","year":"2009","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.bulcan.2017.05.009_bib0735","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/leu.2012.105","article-title":"High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses","volume":"26","author":"Metzelder","year":"2012","journal-title":"Leukemia."},{"issue":"12","key":"10.1016\/j.bulcan.2017.05.009_bib0740","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.bbmt.2011.07.011","article-title":"Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib","volume":"17","author":"Sharma","year":"2011","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.009_bib0745","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/ejh.12647","article-title":"High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation","volume":"96","author":"De Freitas","year":"2016","journal-title":"Eur J Haematol"},{"issue":"26","key":"10.1016\/j.bulcan.2017.05.009_bib0750","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1200\/JCO.2012.44.7961","article-title":"Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change","volume":"31","author":"Christopeit","year":"2013","journal-title":"J Clin Oncol."},{"issue":"19","key":"10.1016\/j.bulcan.2017.05.009_bib0755","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/cncr.30130","article-title":"Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"122","author":"Giebel","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2017.05.009_bib0760","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.bbmt.2011.12.587","article-title":"Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"18","author":"Caocci","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.009_bib0765","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cncr.29141","article-title":"Phase\u00a01\/2\u00a0study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome \u2013 positive acute lymphoblastic leukemia","volume":"121","author":"Shimoni","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2017.05.009_bib0770","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood.V67.1.195.195","article-title":"The risks of central nervous system relapse and leukoencephalopathy in patients receiving marrow transplants for acute leukemia","volume":"67","author":"Thompson","year":"1986","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2017.05.009_bib0775","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/1097-0142(19891101)64:9<1796::AID-CNCR2820640907>3.0.CO;2-7","article-title":"Central nervous system relapses after bone marrow transplantation for acute lymphoblastic leukemia in remission","volume":"64","author":"Ganem","year":"1989","journal-title":"Cancer."},{"issue":"4","key":"10.1016\/j.bulcan.2017.05.009_bib0780","first-page":"637","article-title":"Central nervous system relapse after bone marrow transplantation for acute leukemia in first remission","volume":"17","author":"Singhal","year":"1996","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib0785","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bmt.2010.121","article-title":"Use of intrathecal chemoprophylaxis in children after SCT and the risk of central nervous system relapse","volume":"46","author":"Rubin","year":"2011","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"10.1016\/j.bulcan.2017.05.009_bib0790","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.bbmt.2014.07.005","article-title":"Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation","volume":"20","author":"Hamdi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2017.05.009_bib0795","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.bbmt.2008.07.002","article-title":"Central nervous system relapse of leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Oshima","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"issue":"7","key":"10.1016\/j.bulcan.2017.05.009_bib0800","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.bbmt.2014.03.030","article-title":"Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblastic leukemia","volume":"20","author":"Ge","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bulcan.2017.05.009_bib0805","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.bbmt.2014.09.001","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement","volume":"20","author":"Aoki","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib0810","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.bbmt.2014.11.683","article-title":"Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation","volume":"21","author":"Bar","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib0815","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3109\/10428194.2012.720375","article-title":"Extramedullary relapse following reduced intensity allogeneic hematopoietic cell transplant for adult acute myelogenous leukemia","volume":"54","author":"Kogut","year":"2013","journal-title":"Leuk Lymph"},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.009_bib0820","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3324\/haematol.2012.073189","article-title":"Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes","volume":"98","author":"Harris","year":"2013","journal-title":"Haematologica."},{"issue":"11","key":"10.1016\/j.bulcan.2017.05.009_bib0825","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American society for blood and marrow transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib0830","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma working party of the European group for blood and marrow transplantation","volume":"26","author":"Sureda","year":"2008","journal-title":"J Clin Oncol."},{"issue":"10","key":"10.1016\/j.bulcan.2017.05.009_bib0835","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.bbmt.2011.03.010","article-title":"Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation","volume":"17","author":"Ram","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.bulcan.2017.05.009_bib0840","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","article-title":"Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma","volume":"14","author":"Burroughs","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2017.05.009_bib0845","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/sj.bmt.1703895","article-title":"GVHD\u201d: graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning","volume":"31","author":"Porter","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2017.05.009_bib0850","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2008.07349.x","article-title":"Allogeneic transplantation for Hodgkin lymphoma","volume":"143","author":"Peggs","year":"2008","journal-title":"Br J Haematol."},{"issue":"4","key":"10.1016\/j.bulcan.2017.05.009_bib0855","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2003-05-1513","article-title":"Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses","volume":"103","author":"Peggs","year":"2004","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.009_bib0860","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1704621","article-title":"Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose. GVHD and disease response","volume":"34","author":"Anderlini","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.009_bib0865","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.13441","article-title":"Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome","volume":"94","author":"Robinson","year":"2009","journal-title":"Haematologica."},{"issue":"10","key":"10.1016\/j.bulcan.2017.05.009_bib0870","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.bmt.1704942","article-title":"Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen","volume":"35","author":"Anderlini","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.009_bib0875","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3324\/haematol.11828","article-title":"Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D.\u00a0Anderson Cancer Center experience","volume":"93","author":"Anderlini","year":"2008","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib0880","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2011-12-397893","article-title":"Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation","volume":"120","author":"Gopal","year":"2012","journal-title":"Blood."},{"issue":"No. 5 [February 10]","key":"10.1016\/j.bulcan.2017.05.009_bib0885","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1200\/JCO.2012.43.6832","article-title":"Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission","volume":"31","author":"Theurich","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2017.05.009_bib0890","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/bmt.2016.129","article-title":"Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2017.05.009_bib0895","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.bbmt.2014.05.024","article-title":"Bendamustine combined with donor lymphocytes infusion in Hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation","volume":"20","author":"Sala","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.009_bib0900","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/bmt.2015.346","article-title":"Major clinical response to nivolumab in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplantation","volume":"51","author":"Yared","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib0905","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/bmt.2015.266","article-title":"Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation","volume":"51","author":"Angenendt","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.009_bib0910","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/bmt.2016.20","article-title":"Hematopoietic stem cell transplantation in Europe 2014: more than 40,000\u00a0transplants annually","volume":"51","author":"Passweg","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"10.1016\/j.bulcan.2017.05.009_bib0915","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.bulcan.2017.05.009_bib0920","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/PPO.0b013e31826b124c","article-title":"Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma","volume":"18","author":"Khouri","year":"2012","journal-title":"Cancer J"},{"issue":"10","key":"10.1016\/j.bulcan.2017.05.009_bib0925","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1700781","article-title":"Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect","volume":"19","author":"van Besien","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2017.05.009_bib0930","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(14)70161-5","article-title":"Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase\u00a02\u00a0trial","volume":"15","author":"Glass","year":"2014","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib0935","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2141.2003.04446.x","article-title":"Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma","volume":"122","author":"Shimoni","year":"2003","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.009_bib0940","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bmt.2015.339","article-title":"Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation","volume":"51","author":"Link","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"23","key":"10.1016\/j.bulcan.2017.05.009_bib0945","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2009.26.9100","article-title":"T-cell\u2013depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma","volume":"28","author":"Thomson","year":"2010","journal-title":"J Clin Oncol."},{"issue":"14","key":"10.1016\/j.bulcan.2017.05.009_bib0950","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/blood-2009-11-255182","article-title":"Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma","volume":"115","author":"Lambert","year":"2010","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.bulcan.2017.05.009_bib1015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1705074","article-title":"Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation","volume":"36","author":"Russell","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2017.05.009_bib0960","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/asheducation-2010.1.489","article-title":"Ultra high-risk myeloma","volume":"2010","author":"Avet-Loiseau","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.bulcan.2017.05.009_bib0965","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/bmt.2015.325","article-title":"Allogeneic stem cell transplantation for multiple myeloma is there a future?","volume":"51","author":"Dhakal","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"9","key":"10.1016\/j.bulcan.2017.05.009_bib0970","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON\u00a076\u00a0Trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.bulcan.2017.05.009_bib0975","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.bbmt.2014.04.014","article-title":"Resource for clinical investigation in blood and marrow transplantation. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation","volume":"20","author":"Alsina","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib0980","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/bmt.2012.142","article-title":"Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory\/relapsed myeloma patients","volume":"48","author":"Kr\u00f6ger","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.009_bib0985","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.exphem.2006.02.020","article-title":"Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status","volume":"34","author":"Kr\u00f6ger","year":"2006","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1016\/j.bulcan.2017.05.009_bib0990","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3324\/haematol.2012.069328","article-title":"Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy","volume":"98","author":"Coman","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bulcan.2017.05.009_bib0995","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/bmt.2013.219","article-title":"A prospective study of lenalidomide monotherapy for relapse after allo-SCT for multiple myeloma","volume":"49","author":"Bensinger","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib1000","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3324\/haematol.12184","article-title":"High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma","volume":"93","author":"El-Cheikh","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.009_bib1005","first-page":"837","article-title":"Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation","volume":"91","author":"Runo","year":"2006","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.009_bib1010","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.bbmt.2012.10.032","article-title":"Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation","volume":"19","author":"Montefusco","year":"2013","journal-title":"Biol Blood Marrow Transplant."}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455117302746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455117302746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T02:02:04Z","timestamp":1719626524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455117302746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":101,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0007455117302746"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.05.009","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strat\u00e9gies pr\u00e9ventives et th\u00e9rapeutiques de la rechute apr\u00e8s allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}